NL-OMON38506已完成不适用
A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, 3-WAY CROSSOVER STUDY TO COMPARE THE RATE AND EXTENT OF RIVASTIGMINE ABSORPTION FROM A 7 DAY RIVASTIGMINE TRANSDERMAL SYSTEM (7-DAY RTS) WITH AND WITHOUT OVERLAY WITH 24-HR EXELON® PATCH APPLIED DAILY FOR 7 DAYS IN HEALTHY MALE AND FEMALE SUBJECTS - Rivastigmine transdermal patch study
oven Pharmaceuticals, Inc.0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male and female subjects
- •18-65 yrs, inclusive
- •BMI: 18.0-29.9 kg/m2, inclusive
- •non-smoking
- •light skin color
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A RANDOMIZED, SINGLE-CENTER, OPEN-LABEL, 5-WAY CROSSOVER, SINGLE-DOSE BIOAVAILABILITY/BIOEQUIVALENCE COMPARISON OF BRIVARACETAM ORAL TABLETS (10MG, 50MG, 75MG, AND 100MG) AND BRIVARACETAM INTRAVENOUS BOLUS INJECTION (100MG) IN HEALTHY VOLUNTEERSattacksepileptic seizures10039911NL-OMON38511CB Pharma25
已完成
不适用
A single-center, randomized, open-label, 3 way crossover study to evaluate the single and multiple dose pharmacokinetic profile of HP-5000 compared to PENNSAID® 2% in healthy volunteersonstekingenInflammationNL-OMON42086PRA Health Sciences18
已完成
不适用
SINGLE CENTER, OPEN LABEL, RANDOMIZED TWO-WAY CROSSOVER STUDY OF THE EFFECT OF LACOSAMIDE 200MG TWICE DAILY ON THE SINGLE-DOSE PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN (25 MG) IN HEALTHY MALE VOLUNTEERSseizures (attacks)10039911EpilepsyNL-OMON37817CB Pharma16
已完成
不适用
SWITCH TO MK-1439A FROM A RITONAVIR-BOOSTED PI-CONTAINING REGIMEN IN HIV-1-INFECTED SUBJECTS.PER-031-15Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc.,7
已完成
1 期
A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, 3-WAY CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF BRIVARACETAM INTRAVENOUS FORMULATION GIVEN AS A 2-MINUTE IV BOLUS INJECTION, A 15-MINUTE IV INFUSION, AND AN ORALLY-DOSED TABLET IN HEALTHY MALE JAPANESE SUBJECTSJPRN-jRCT2080223863CB Japan Co., Ltd.24